Molecular mechanisms and emerging therapeutics for osteoporosis
JY Noh, Y Yang, H Jung - International journal of molecular sciences, 2020 - mdpi.com
Osteoporosis is the most common chronic metabolic bone disease. It has been estimated
that more than 10 million people in the United States and 200 million men and women …
that more than 10 million people in the United States and 200 million men and women …
Prospect of mesenchymal stem cells in therapy of osteoporosis: a review
Osteoporosis is a systemic skeletal disease associated with reduced bone strong point that
results in raised fracture risk, with decreased bone strength, leading to reduced bone …
results in raised fracture risk, with decreased bone strength, leading to reduced bone …
Advances in the occurrence and biotherapy of osteoporosis
Z Zou, W Liu, L Cao, Y Liu, T He… - Biochemical Society …, 2020 - portlandpress.com
Osteoporosis (OP) is a bone metabolic disease, is characterized by degeneration of bone
structure and decreased bone mass. It happens in more than 1/3 women and 1/5 men of …
structure and decreased bone mass. It happens in more than 1/3 women and 1/5 men of …
Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab …
In vitro data suggest that myokine irisin may affect bone metabolism by promoting osteoblast
differentiation while inhibiting osteoclast differentiation. In this study, circulating irisin levels …
differentiation while inhibiting osteoclast differentiation. In this study, circulating irisin levels …
Stem cell therapy for osteoporosis
Osteoporosis is a debilitating disease that affects millions of people worldwide. Current
osteoporosis treatments are predominantly bone-resorbing drugs that are associated with …
osteoporosis treatments are predominantly bone-resorbing drugs that are associated with …
The underlying pathophysiology and therapeutic approaches for osteoporosis
H Awasthi, D Mani, D Singh… - Medicinal research …, 2018 - Wiley Online Library
With an increase in the ageing population worldwide, the prevalence of osteoporosis
increases at an alarming rate in both male and female irrespective of their ethnicity. At …
increases at an alarming rate in both male and female irrespective of their ethnicity. At …
Bazedoxifene for the treatment of osteoporosis
Introduction: Bazedoxifene (BZD) is a third-generation selective estrogen receptor modulator
approved for the treatment of postmenopausal osteoporosis with additional favorable effects …
approved for the treatment of postmenopausal osteoporosis with additional favorable effects …
Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy
Osteoporosis is age-related deterioration in bone mass and micro-architecture. Denosumab
is a novel human monoclonal antibody for osteoporosis. It is a receptor activator of nuclear …
is a novel human monoclonal antibody for osteoporosis. It is a receptor activator of nuclear …
Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series
S Aljohani, R Gaudin, J Weiser, M Tröltzsch… - Journal of Cranio …, 2018 - Elsevier
Purpose Osteonecrosis of the jaw has been recently reported in patients receiving
denosumab for the treatment of metastatic bone disease and osteoporosis. It is essential to …
denosumab for the treatment of metastatic bone disease and osteoporosis. It is essential to …
RANKL regulates male reproductive function
Infertile men have few treatment options. Here, we demonstrate that the transmembrane
receptor activator of NF-kB ligand (RANKL) signaling system is active in mouse and human …
receptor activator of NF-kB ligand (RANKL) signaling system is active in mouse and human …